Daniele Focosi to Spike Glycoprotein, Coronavirus
This is a "connection" page, showing publications Daniele Focosi has written about Spike Glycoprotein, Coronavirus.
Connection Strength
0.308
-
Emergence of SARS-COV-2 Spike Protein Escape Mutation Q493R after Treatment for COVID-19. Emerg Infect Dis. 2021 Oct; 27(10):2728-2731.
Score: 0.106
-
Neutralising antibody escape of SARS-CoV-2 spike protein: Risk assessment for antibody-based Covid-19 therapeutics and vaccines. Rev Med Virol. 2021 11; 31(6):e2231.
Score: 0.103
-
Symptomatic SARS-CoV-2 infections after full schedule BNT162b2 vaccination in seropositive healthcare workers: a case series from a single institution. Emerg Microbes Infect. 2021 Dec; 10(1):1254-1256.
Score: 0.027
-
SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal Antibodies. Viruses. 2021 06 23; 13(7).
Score: 0.026
-
Imported SARS-CoV-2 Variant P.1 in Traveler Returning from Brazil to Italy. Emerg Infect Dis. 2021 04; 27(4):1249-1251.
Score: 0.026
-
Characterization of a Lineage C.36 SARS-CoV-2 Isolate with Reduced Susceptibility to Neutralization Circulating in Lombardy, Italy. Viruses. 2021 07 31; 13(8).
Score: 0.007
-
SARS-CoV-2 B.1.1.7 reinfection after previous COVID-19 in two immunocompetent Italian patients. J Med Virol. 2021 Sep; 93(9):5648-5649.
Score: 0.007
-
Anti-SARS-CoV-2 RBD IgG responses in convalescent versus naïve BNT162b2 vaccine recipients. Vaccine. 2021 04 28; 39(18):2489-2490.
Score: 0.006